Meeting Banner
Abstract #4189

Evaluation of Macrocyclic Gadolinium-Based Contrast Agent Retention in a Longitudinal Multiple Sclerosis Study

Gabriel Kocevar1, Salem Hannoun2, Claudio Stamile1, François Cotton1,3, Françoise Durand-Dubief1,4, and Dominique Sappey-Marinier1,5

1CREATIS Laboratory, Université Claude Bernard - Lyon 1, Lyon, France, 2Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut, Beirut, Lebanon, 3Centre Hospitalier Lyon-Sud - Service de Radiologie, Hospices Civils de Lyon, Lyon, France, 4Hôpital Neurologique - Service de Neurologie A, Hospices Civils de Lyon, Lyon, France, 5CERMEP - Imagerie du Vivant, Université de Lyon, Lyon, France

Gadolinium-based contrast agents (GBCA) are commonly used to identify blood-brain-barrier disruption. Recent studies reported gadolinium deposition in deep gray matter (GM) structures, following serial injections of linear complexes of GBCA. While it is recognized that linear complexes of GBCA may lead to gadolinium retention in brain, macrocyclic GBCA should also be evaluated. In this study, we investigated the effect of serial macrocyclic GBCA injections in 92 Multiple Sclerosis patients followed during seven years. Our results did not show any significant signal intensity changes in deep GM structures, and particularly in the dentate nuclei and the globus pallidus.

This abstract and the presentation materials are available to members only; a login is required.

Join Here